Bio-Gene Technology (ASX: BGT) is charting a course for its lead compound Flavocide, targeting an APVMA submission in March 2027.
Key OECD toxicology studies, including for neurotoxicity and reproductive effects, are underway with data due in May and September 2026 respectively.
Additional Good Laboratory Practice (GLP) studies, including OECD 417 part 2 (ADME/metabolism) and a 90-day rat study (OECD 408), are planned through early 2027.
Toxicology Studies Underway
The company is conducting neurotoxicity (OECD 424, data due May 2026) and reproductive toxicity (OECD 443, data due September 2026) studies.
A 90-day rat study (OECD 408) and other GLP studies are planned for 2026-2027.
These four major toxicity studies constitute approximately 55% of the total study duration.
Commercial Strategy & Global Reach
Bio-Gene plans to pursue commercialisation through licensing arrangements and formulated-product registrations with partners.
Following initial Australian registration, the company intends to target the US and other major global markets.
The GLP 5-batch analysis of technical Flavocide material is completed or in its final stages, with stability studies planned.
Funding and Operations
For the half-year ended 31 December 2025, Bio-Gene Technology reported a net loss after tax of approximately $1.4 million.
Cash on hand at 31 December 2025 was approximately $1.08 million.
The company has previously noted a 'material going-concern risk' due to ongoing operating losses and negative cash flow, indicating a reliance on anticipated fundraising to continue operations.
Recent quarterly reports also indicate a continued net cash burn driven by research and development, and commercialisation spend.
Flavocide Poised for Regulatory Submission
Bio-Gene Technology has outlined a clear regulatory timeline for its lead compound, Flavocide, targeting an APVMA submission in March 2027 supported by ongoing toxicology studies.
While this progress is positive, the company continues to navigate financial risks, with a material going-concern uncertainty and reliance on future fundraising.
